Celgene International II

Celgene is a global biopharmaceutical company specializing in the discovery and development of innovative treatments for cancer and inflammatory diseases. Following its landmark $74 billion acquisition by Bristol Myers Squibb in 2019, the company operates as a core subsidiary within the BMS oncology and hematology portfolio. Celgene is widely recognized for its pioneering work in protein degradation through its IMiD (immunomodulatory imide drug) platform, which produced blockbuster therapies like Revlimid and Pomalyst. The company also expanded into advanced biologics and cell therapies, resulting in the approval of CAR-T treatments such as Abecma and Breyanzi. Celgene International II serves as a critical legal and operational entity for the company's international business activities, particularly in Europe.